Clinical Overview
Lamivudine Tablets (100mg) is a synthetic cytosine nucleoside analogue reverse transcriptase inhibitor on the WHO Model List of Essential Medicines. Intracellular lamivudine triphosphate incorporates into viral DNA, competitively inhibiting HBV DNA polymerase and causing DNA chain termination. Indicated for the treatment of chronic hepatitis B infection in patients with evidence of hepatitis B viral replication and active liver inflammation.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally 100 mg once daily with or without food with water. Dose must be reduced in patients with renal impairment (CrCl < 50 mL/min).
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Malaise, fatigue, headache, abdominal discomfort, diarrhea. Rare/Severe: HBV viral flare on discontinuation, emergence of YMDD mutant resistant strains (up to 70% at 5 years), and lactic acidosis.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black Box Warning: Severe exacerbations of hepatitis B on treatment cessation. High rate of HBV resistance (YMDD mutation) compared to entecavir or tenofovir; modern guidelines prefer entecavir or TAF as first-line agents.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or gastrointestinal treatment recommendations. Always consult a registered gastroenterologist or qualified medical practitioner before initiating, altering, or discontinuing any gastrointestinal medication or digestive therapy.
Abacavir 600mg + Dolutegravir 50mg + Lamivudine 300mg Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Abacavir 600mg + Lamivudine 300mg Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.
Dolutegravir (50Mg) + Lamivudine (300Mg) + Tenofovir Disoproxil Fumarate (300Mg) Tablets
Antiretroviral therapy (ART) formulation comprising nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), or boosted protease inhibitors (PIs). Engineered to suppress HIV-1 viral replication to undetectable levels, halt disease progression, and restore CD4 immune function.